Johnson & Johnson (J&J) announced on November 17 that it entered into an agreement to acquire Halda Therapeutics. The purchase price is $3.05 billion.
Founded by Yale scientist, Professor Craig Crews, Halda Therapeutics is a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity Targeting Chimera platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer.
J&J is one of the largest global healthcare and pharmaceutical companies with more than 130,000 employees worldwide. Its business lines include pharmaceuticals, medical devices and consumer healthcare products. According to its most recent financial report, J&J’s revenue for the full year 2024 was $88.8 billion.
This is J&J’s second acquisition of 2025. In January, the company purchased Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, for $14.6 billion.
According to data captured in the LevinPro HC database, this transaction represents the 119th Biotechnology transaction of 2025. There were 135 Biotechnology transactions announced in 2024, and 160 announced in 2023.
